Kimberly-Clark Is Buying Tylenol Maker Kenvue in Cash and Stock Deal Worth –$48b
Posted2 months agoActive2 months ago
apnews.comOtherstory
calmneutral
Debate
20/100
M&aPharmaceuticalsConsumer Goods
Key topics
M&a
Pharmaceuticals
Consumer Goods
Kimberly-Clark is acquiring Kenvue, the maker of Tylenol, in a $48B cash and stock deal, sparking discussions about potential connections to past controversies.
Snapshot generated from the HN discussion
Discussion Activity
Light discussionFirst comment
4h
Peak period
2
4-6h
Avg / period
1.5
Key moments
- 01Story posted
Nov 3, 2025 at 2:57 PM EST
2 months ago
Step 01 - 02First comment
Nov 3, 2025 at 7:15 PM EST
4h after posting
Step 02 - 03Peak activity
2 comments in 4-6h
Hottest window of the conversation
Step 03 - 04Latest activity
Nov 4, 2025 at 9:26 AM EST
2 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
Discussion (3 comments)
Showing 3 comments
snypher
2 months ago
1 replyNot sure where the '-' came from, it's regular +$48b
healsdataAuthor
2 months ago
Ah crap. I tried to put ~ since the original headline had the word "about" but I must have typo'd.
treetalker
2 months ago
Would be interesting to see whether and how anyone at Kimberly-Clark, or any of its shareholders, cozied up to Trump and/or RFK Jr. before the whole MAHA "acetaminophen causes autism" bit happened; and when, exactly, Kimberly Clark started looking into acquiring Kenvue.
View full discussion on Hacker News
ID: 45803664Type: storyLast synced: 11/17/2025, 7:50:52 AM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.